Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized patients with acute or chronic liver disease~* Type I HRS~* Aged greater than or equal to 18~* Non-pregnant~Exclusion Criteria:~* Allergy or hypersensitivity to PTX or intolerance to methylxanthines (e.g. caffeine, theophylline)~* Concurrent use of nephrotoxic drugs~* Age less than 18~* Pregnancy~* Uncontrolled bacterial infection~* Renal parenchymal disease (e.g. acute tubular necrosis, glomerular disease, interstitial nephritis and urinary obstruction)~* Shock~* TNF alpha antagonist use~* Subject is institutionalized or a prisoner~* Recent cerebral or retinal hemorrhage (contraindication to PTX)~* Severe or poorly controlled cardiovascular disease as determined by the principal investigator to hinder the ability to adhere to study protocols

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Pentoxyfylline 400mg three times a day or 400mg twice a day for eGFR 10-50 and 400mg once a day for eGFR \<10 for 90 days in addition to standard AMO therapy
- Placebo (Type: PLACEBO_COMPARATOR): This is a standard placebo pill.

Based on this trial design, predict the completion outcome and termination type (if applicable).